araag2/HINT huggingface dataset:
Clinical trial NCT01197560 (phase 2/phase 3, status: completed)
Conditions: diffuse large b-cell lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: lenalidomide, gemcitabine, oxaliplatin, rituximab, etoposide
SMILES: NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, ClCCN(CCCl)P1(=O)NCCCO1, OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically proven Diffuse Large B-Cell Lymphoma (DLBCL).

          -  Relapsed or refractory to combination chemotherapy for DLBCL that contains rituximab
             and an anthracycline, and one additional combination chemotherapy or stem cell
             transplant.

          -  Measurable DLBCL disease by computed tomograph (CT) / magnetic resonance imagining
             (MRI).

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 - 2.

        Exclusion Criteria:

          -  Diagnosis of lymphoma histologies other than DLBCL.

          -  History of malignancies, other than DLBCL, unless the patient has been disease free
             for 3 years or more.

          -  Eligible for autologous stem cell transplant.

          -  Known seropositive for, or history of, active human immunodeficiency virus (HIV)
             hepatitis B virus (HBV), hepatitis C virus (HCV)

          -  Neuropathy grade 4.
Clinical trial NCT00516750 (phase 2, status: terminated)
Conditions: bladder cancer
ICD codes: D30.3, C67.5, C67.9, C79.11, C67.0, C67.1, D41.4
Drugs: cisplatin, doxorubicin hydrochloride, methotrexate, vinblastine
SMILES: [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, N[C@@H](CCCNC(N)=N)C(O)=O
Reason stopped: 
    withdrawn due to lack of enrollment.
  
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Diagnosis of invasive bladder cancer

          -  Must be confirmed by chest and abdominal CT scan OR pelvic MRI scan and transurethral
             biopsy (with definitive muscle invasion > T2) within 4 weeks prior to registration

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-1

          -  WBC ≥ 3,000/mm^3

          -  Neutrophil count ≥ 1,500/mm^3

          -  Platelet count ≥ 100,000/mm^3

          -  Total bilirubin ≤ 1.5 mg/dL

          -  Serum creatinine ≤ 1.5 mg/dL

          -  AST and ALT ≤ 2.5 x upper limit of normal

          -  Not pregnant

          -  No liver cirrhosis

          -  No ischemic cardiovascular disease or arrhythmia for which treatment is necessary

          -  No cardiac infarction within the past 6 months

          -  No interstitial pneumonia, pulmonary fibrosis, or any other diseases by which oxygen
             inhalation therapy is needed

          -  No active cancerous lesion other than upper urinary tract tumor

          -  No high fever or any other infectious symptom

          -  No uncontrolled hypertension or diabetes mellitus

        PRIOR CONCURRENT THERAPY:

          -  No prior systemic chemotherapy
Clinical trial NCT01078623 (phase 2, status: completed)
Conditions: chronic obstructive pulmonary disease
ICD codes: J44.9, J44.1, J44.0
Drugs: aclidinium 200 μg / formoterol 12 μg, placebo, formoterol 12 μg, aclidinium 200 μg, aclidinium 200 μg / formoterol 6 μg
SMILES: OC(C(=O)O[C@H]1C[N+]2(CCCOC3=CC=CC=C3)CCC1CC2)(C1=CC=CS1)C1=CC=CS1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1, OC(C(=O)O[C@H]1C[N+]2(CCCOC3=CC=CC=C3)CCC1CC2)(C1=CC=CS1)C1=CC=CS1, OC(C(=O)O[C@H]1C[N+]2(CCCOC3=CC=CC=C3)CCC1CC2)(C1=CC=CS1)C1=CC=CS1
Eligibility criteria:

        Inclusion Criteria:

          1. Adult male or non-pregnant, non-lactating female aged between 40 and 80 years old,
             both inclusive.

          2. Patient with a clinical diagnosis of stable moderate to severe COPD according to the
             GOLD classification

          3. Current, or ex-cigarette smoker with a smoking history of at least 10 pack-years.

          4. Patient whose FEV1 at the Screening Visit measured between 10-15 minutes post
             inhalation of 400 mcg of salbutamol is 30% FEV1 <80% of the predicted normal value
             (i.e., 100 x Post-salbutamol < FEV1/ Predicted FEV1 must be < 80% and ≥ 30%).

          5. Patient whose FEV1/FVC at the Screening Visit measured between 10-15 minutes post
             inhalation of 400 mcg of salbutamol is < 70% (i.e., 100 x Post-salbutamol FEV1 /FVC <
             70%).

          6. Patient who is eligible and able to participate in the trial and who consent to do so
             in writing after the purpose and nature of the investigation have been explained.

          7. Patient whose COPD symptoms and FEV1 values at the time of randomisation are stable
             compared to the Screening Visit, according to the investigator's medical judgment

        Exclusion Criteria:

          1. History or current diagnosis of asthma or exercise-induced bronchospasm.

          2. Clinically significant respiratory conditions at the time of Inform Consent signature

          3. Hospitalisation due to COPD exacerbation within the previous 3 months.

          4. Signs of a COPD exacerbation or respiratory infection (including the upper respiratory
             tract) within the previous 6 weeks.

          5. Patient who has a resting systolic blood pressure ≥ 200 mmHg, a resting diastolic
             blood pressure ≥ 120 mmHg or a resting heart rate ≥ 105 bpm at screening visit.

          6. Clinically significant cardiovascular conditions

          7. Presence of symptomatic prostatic hypertrophy and/or bladder neck obstruction.

          8. Presence of narrow-angle glaucoma.

          9. QTc [calculated according to Bazett's formulae (QTc=QT/RR1/2) above 470 milliseconds
             in the ECG performed at Screening Visit,

         10. Patient who does not maintain regular day/night, waking/sleeping cycles
Clinical trial NCT00683722 (phase 2, status: completed)
Conditions: pulmonary disease, chronic obstructive, pulmonary emphysema, chronic bronchitis
ICD codes: J44.9, J44.1, J44.0, J43.0, J41.0, J41.1, J42, J41.8, J40
Drugs: prochymal™, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Subject must have a diagnosis of moderate or severe COPD

          -  Subject must have a post-bronchodilator FEV1/FVC ratio < 0.7

          -  Subject must have a post-bronchodilator FEV1 % predicted value ≥ 30% and < 70%

          -  Subject must be between 40 and 80 years of age, of either sex, and of any race

          -  Subject must be a current or ex-smoker, with a cigarette smoking history of ≥ 10 years
             or > 10 pack-years

        Exclusion Criteria:

          -  Subject has been diagnosed with asthma or other clinically relevant lung disease other
             than COPD (e.g. restrictive lung diseases, sarcoidosis, tuberculosis, idiopathic
             pulmonary fibrosis, bronchiectasis, or lung cancer)

          -  Subject has been diagnosed with α1-Antitrypsin deficiency

          -  Subject has a body mass greater than 150 kg (330 lb) or less than 40 kg (88 lb)

          -  Subject has active infection

          -  Subject has had a significant exacerbation of COPD or has required mechanical
             ventilation within 4 weeks of screening

          -  Subject with clinically relevant uncontrolled medical condition not associated with
             COPD

          -  Subject has documented history of uncontrolled heart failure

          -  Subject has pulmonary hypertension due to left heart condition

          -  Subject has atrial fibrillation or significant congenital heart defect/disease

          -  Subject has initiated pulmonary rehabilitation within 3 months of screening

          -  Subject is allergic to bovine or porcine products

          -  Subject has evidence of active malignancy, or prior history of active malignancy that
             has not been in remission for at least 5 years

          -  Subject has a life expectancy of < 6 months
Clinical trial NCT00274716 (phase 2, status: completed)
Conditions: hypertension
ICD codes: I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, I10
Drugs: mk0736, mk0916, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Hypertension systolic blood pressure (SBP) </= 160mm Hg and diastolic blood pressure
             (DBP): 90-105mm Hg

        Exclusion Criteria:

          -  Pre-menopausal women

          -  patients currently taking more than two (2) blood pressure lowering medications

          -  Body Mas Index (BMI)>40 kg/m2 (morbidly obese patients)

          -  History of Alcohol abuse (<3 Years)

          -  History of diabetes,chronic kidney disease, Active liver disease, recent heart attack
             or stroke
Clinical trial NCT00109850 (phase 2, status: terminated)
Conditions: esophageal cancer
ICD codes: K22.2, K22.81, Q39.4, P78.83, I85.00, I85.01, I85.10
Drugs: cisplatin, irinotecan hydrochloride
SMILES: [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, CCC1=C2CN3C(=CC4=C(COC(=O)[C@]4(O)CC)C3=O)C2=NC2=CC=C(OC(=O)N3CCC(CC3)N3CCCCC3)C=C12
Reason stopped: 
    closed due to poor accrual
  
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed primary squamous cell carcinoma or adenocarcinoma of the
             thoracic esophagus (≥ 20 cm from the incisors*) or the gastroesophageal junction
             (confined to ≤ 2 cm into the gastric cardia)

               -  Disease confined to the esophagus or peri-esophageal soft tissue

               -  T4, M0 disease

               -  Surgically unresectable disease by esophageal endoscopic ultrasonography OR
                  medically unresectable disease

        NOTE: *Patients with primary disease < 26 cm from the incisors must undergo bronchoscopy
        AND have negative cytology within the past 4 weeks

          -  Measurable or non-measurable disease by x-ray, CT scan and/or MRI, or physical
             examination within the past 4 weeks (for measurable disease) or within the past 6
             weeks (for non-measurable disease)

          -  Tumor specimens available

          -  No recurrent disease

        PATIENT CHARACTERISTICS:

        Age

          -  18 and over

        Performance status

          -  Zubrod 0-2

        Life expectancy

          -  Not specified

        Hematopoietic

          -  Absolute neutrophil count (ANC) ≥ 1,500/mm^3

          -  White Blood Cell (WBC) count ≥ 3,000/mm^3

          -  Platelet count ≥ 100,000/mm^3

          -  Hemoglobin ≥ 10.0 g/dL

        Hepatic

          -  Albumin normal

          -  Bilirubin normal

          -  Alkaline phosphatase normal

          -  Serum glutamic oxaloacetic transaminase (SGOT) or Serum glutamic pyruvic transaminase
             (SGPT) ≤ 2.5 times upper limit of normal

        Renal

          -  Creatinine clearance > 50 mL/min

        Other

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception

          -  No prior severe reaction to monoclonal antibodies

          -  No other malignancy within the past 5 years except adequately treated basal cell or
             squamous cell skin cancer or carcinoma in situ of the cervix

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  Not specified

        Chemotherapy

          -  No prior chemotherapy for esophageal cancer

        Endocrine therapy

          -  Not specified

        Radiotherapy

          -  No prior radiotherapy for esophageal cancer

          -  No concurrent intensity modulated radiotherapy

          -  No concurrent cobalt-60

        Surgery

          -  No prior surgical resection or attempted surgical resection of esophageal cancer
Clinical trial NCT00430300 (phase 2, status: terminated)
Conditions: pulmonary disease, chronic obstructive
ICD codes: J44.9, J44.1, J44.0
Drugs: uk-432,097, placebo
SMILES: [H][C@@]1(O)[C@]([H])(O)[C@]([H])(O[C@@]1([H])N1C=NC2=C(NCC(C3=CC=CC=C3)C3=CC=CC=C3)N=C(N=C12)C(=O)NCCN=C(O)NC1CCN(CC1)C1=CC=CC=N1)C(O)=NCC, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with a diagnosis, for at least 6 months, of moderate to severe COPD (GOLD)
             and who meet the criteria for Stage II-III disease

          -  Patients must have a smoking history of at least 10 pack-years

          -  Patients must have stable disease for at least 1 month prior to screening.

        Exclusion Criteria:

          -  More than 2 exacerbations of COPD in the preceding year

          -  History of a lower respiratory tract infection or significant disease instability
             during the month proceding screening or during the time between screen and
             randomization.

          -  History or presence of respiratory failure, cor pulmonale or right ventricular failure
Clinical trial NCT00065117 (phase 2, status: terminated)
Conditions: colorectal neoplasms, metastases, neoplasm
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: zd6126, placebo, 5-fluorouracil, leucovorin, oxaliplatin
SMILES: COC1=C(OC)C(OC)=C2C(CC[C@H](NC(C)=O)C3=C2C=CC(OP(O)(O)=O)=C3)=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, FC1=CNC(=O)NC1=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Metastatic colorectal carcinoma

          -  Suitable for first-line treatment of metastatic disease

        Exclusion Criteria:

          -  Peripheral neuropathy greater than Grade 1

          -  Adjuvant therapy within 6 months prior to study treatment

          -  Prior oxaliplatin

          -  Prior pelvic or whole abdomen radiation

          -  Any history of coronary angioplasty or history of myocardial infarction
Clinical trial NCT00396266 (phase 2, status: completed)
Conditions: multiple myeloma, lymphoma, non-hodgkin
ICD codes: C90.01, C90.02, C90.00, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: g-csf plus plerixafor
SMILES: C(N1CCCNCCNCCCNCC1)C1=CC=C(CN2CCCNCCNCCCNCC2)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of non-Hodgkin's lymphoma (NHL) or multiple myoloma (MM) eligible for
             autologous transplantation

          -  No more than 3 prior regimens of chemotherapy

          -  More than 4 weeks since last cycle of chemotherapy. Patient recovered from all acute
             toxic effects of prior chemotherapy.

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          -  White blood cell (WBC) count >3.0*10^9/L

          -  Absolute polymorphonuclear cells (PMN) count >1.5*10^9/L

          -  Platelet (PLT) count >100*10^9/L

          -  Serum creatinine <=2.2 mg/dL

          -  Serum glutamic oxaloacetic transaminase (SGOT), serum glutamic pyruvic transaminase
             (SGPT) and total bilirubin <2 x upper limit of normal (ULN)

          -  Left ventricle ejection fraction >45% by normal echocardiogram or multiple-gated
             acquisition (MUGA) scan

          -  Forced expiratory volume of the lung in the first second (FEV1) >60% of predicted or
             diffusing capacity of the lung for carbon monoxide (DLCO) >45% of predicted

          -  Negative for human immunodeficiency virus (HIV) type 1

          -  Women of child bearing potential agreed to use an approved form of contraception.

        Exclusion Criteria:

          -  • Patients who have failed previous collections

               -  Brain metastases or carcinomatous meningitis

               -  History of ventricular arrhythmias

               -  A co-morbid condition which, in the view of the investigator, renders the patient
                  at high risk for treatment complications

               -  A residual acute medical condition resulting from prior chemotherapy

               -  Acute infection

               -  Fever (temp >38°C/100.4°F)

               -  Patients whose actual body weight exceeds 150% of their ideal body weight

               -  History of paresthesias (at least Grade 2)

               -  Patients who previously received experimental therapy within 4 weeks of enrolling
                  in this study or who are currently enrolled in another experimental study during
                  the mobilization period

               -  Positive pregnancy test in female patients

               -  Lactating females

               -  Patients of child-bearing potential unwilling to implement adequate birth
                  control.

               -  Patients who have deterioration of their clinical status or laboratory parameters
                  between the time of enrolment and transplant (such that they no longer meet entry
                  criteria) may be removed from study at the discretion of the treating physician,
                  principal investigator, or sponsor.
Clinical trial NCT00694603 (phase 2, status: terminated)
Conditions: non-small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: cetuximab
SMILES: [H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O
Reason stopped: 
    slow accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Pathologically confirmed stage IIIB or IV recurrent or progressive NSCLC

          -  Patients must have progressed while receiving treatment with a tyrosine kinase
             inhibitor targeting the EGFR pathway

          -  Measurable disease, as defined by RECIST criteria

          -  Patients must have a suitable frozen or paraffin-embedded tissue sample available for
             EGFR mutational analysis. Prior EGFR mutational analyses are allowable

          -  Patients with asymptomatic brain metastasis are eligible; however, they must have
             completed radiotherapy/radiosurgery at least 3 weeks prior to enrollment and be
             clinically stable

          -  ECOG Performance Status 0-2

          -  18 years of age or older

          -  Negative pregnancy test within 7 days of treatment or be categorized as not of
             child-bearing potential

          -  Bone marrow function, renal function, hepatic function as outlined in protocol

        Exclusion Criteria:

          -  Women who are pregnant of breastfeeding

          -  Active concurrent malignancy

          -  Major thoracic or abdominal surgery within 30 days prior to the first infusion of
             cetuximab

          -  Significant history of uncontrolled cardiac disease

          -  Uncontrolled seizure disorder, or active neurological disease

          -  Prior severe infusion reactions to a monoclonal antibody

          -  Prior chemotherapy regimen within 21 days prior to study entry

          -  Any EGFR tyrosine kinase inhibitor within 14 days of study entry

          -  Radiation therapy within 14 days prior to the first infusion of cetuximab

          -  Acute hepatitis or known HIV

          -  Active or uncontrolled infection

          -  Any concurrent chemotherapy or any other investigational agent(s)
Clinical trial NCT01366014 (phase 2, status: completed)
Conditions: osteoarthritis of the knee
ICD codes: M15.4, M15.0, M16.9, M17.9, M19.011, M19.012, M19.019
Drugs: arry-371797, p38 inhibitor; oral, oxycodone hydrochloride (hcl) extended release (er), opioid agonist; oral, placebo; oral
SMILES: [H][C@@]12OC3=C(OC)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1(O)CCC2=O
Eligibility criteria:

        Key Inclusion Criteria:

          -  Diagnosis of OA of the knee, based on American College of Rheumatology (ACR) criteria,
             confirmed by X-ray (K-L Grade II/III within the last year).

          -  At least moderate or severe pain due to OA in one knee.

          -  On nonsteroidal anti-inflammatory drug (NSAID) 28 days previous to study start and
             willing to continue on NSAID throughout study.

          -  Discontinuation of opioids prior to study start.

          -  Additional criteria exist.

        Key Exclusion Criteria:

          -  Current or recent infection in the last 7 days; infection requiring hospitalization or
             parenteral antibiotics within the last 6 months; history of or currently active
             tuberculosis, hepatitis B or C, or human immunodeficiency virus (HIV).

          -  Surgery on the index knee within the previous 6 months.

          -  Trauma or other surgeries within the previous 8 weeks.

          -  Specific abnormal laboratory values or electrocardiogram abnormalities.

          -  Gastrointestinal surgery that may interfere with motility or absorption.

          -  On non-stable dose of bisphosphonates, or any prior denosumab or parathyroid hormone
             (PTH) therapies.

          -  Prior parenteral tumor necrosis factor (TNF) inhibitor or anti-nerve growth factor
             (NGF) therapies.

          -  Intramuscular, intravenous or oral corticosteroids within the previous 6 weeks.

          -  Intra-articular corticosteroids in the index knee within the previous 8 weeks or
             viscosupplementation in the index knee within the previous 4 months.

          -  Currently enrolled in or participated in another clinical trial within the previous 3
             months.

          -  Additional criteria exist.